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Previewsinterest, among the few described sub-
strates for neddylation are cullin-RING
E3 ligases (CRLs). NEDD8 conjugation to
CRLs leads to a structural reorganization
that results in activation of their ubiquiti-
nation activity (Duda et al., 2008). Neddy-
lated CRLs are unstable, and their
half-lives are regulated by the COP9 sig-
nalosome through deneddylation (Wu
et al., 2005). Previous work has also re-
vealed a complicated interplay between
neddylation and ubiquitination in the
control of p53 activity (Liu and Xirodimas,
2010). For example, MDM2 functions as
an Ub and NEDD8-E3 ligase for p53. The
NEDD8-interacting protein NUB1 can
differentially control p53 modification,
leading to decreased neddylation and
stimulation of monoubiquitination. These
modifications alter the localization of p53
and inhibit its transcriptional activity (Liu
and Xirodimas, 2010). Along these lines,
the conjugation of caspases with UBLs
could perhaps serve both to inhibit
unwanted caspase activity and to localize792 Developmental Cell 19, December 14, 20the active proteins to specific subcellular
regions, thereby providing a solution to
how effector caspases can function in
important nonlethal capacities in the cell
(Bader and Steller, 2009). Indeed, conju-
gation with UBLs can alter protein-protein
interactions and enzymatic activity and
also affect protein localization (Glickman
and Ciechanover, 2002). For example,
conjugation of the nuclear GTPase Ran
with SUMO leads to relocalization of this
protein from the cytosol to the nuclear
pore. The existence of additional possible
UBL modifications has the potential to
add even further complexity to the regula-
tion of protein function in general and IAPs
and caspases in particular. In any event,
the findings of Broemer and colleagues
(2010) provide many new opportunities
to investigate how cells decide between
life and death. Progress in this area also
has the potential for the development of
new strategies for the treatment of human
diseases that are associated with
abnormal regulation of apoptosis.10 ª2010 Elsevier Inc.REFERENCES
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Primary cilia are cell surface organelles that act as sensory antennae for various input signals. In a recent
issue ofNature Cell Biology, Boehlke et al. (2010) demonstrate that bending of cilia regulates cell size through
a signaling pathway involving the LKB1 and mTOR kinases.Science tells us unexpected stories. A
remarkable illustration of this precept is
the series of discoveries in the past
decade that have placed the primary
cilium in the spotlight. Primary cilia are
typical nonmotile organelles that protrude
outside of the surface of the majority
of vertebrate cell types (Gerdes et al.,
2009). The core of the cilium consists of
an axoneme made of nine peripheral
microtubuledoubletsconnected toabasal
body,which is a specialized centriole teth-ered to the plasma membrane by transi-
tion fibers. Biogenesis and maintenance
of the cilium are accomplished by intrafla-
gellar transport (IFT) of proteins and vesi-
cles along the axoneme (Gerdes et al.,
2009). A renewed interest in this structure
came from the finding that two genes,
PKD1 and PKD2, mutated in a dominantly
inherited form of polycystic kidney
disease (PKD) encode components of
the primary cilium (Gerdes et al., 2009).
These two proteins, respectively polycys-tin 1 and 2, formpart of amechanosensory
system that regulates Ca2+ signaling into
renal tubular cells upon deflection of the
cilium by urine flow. However, the molec-
ular events that link faulty cilia to the
formation of cysts were not completely
understood. One model suggests that
inappropriate activation of the mTORC1
pathway would be the primary defect in
PKD pathogenesis (Shillingford et al.,
2006). This idea was reinforced by the
observation that rapamycin, a drug that
Figure 1. Regulation of Cell Size by the Primary Cilium
The axonemal microtubule structure is depicted in red, and the basal body that anchors the cilium in the
plasma membrane is shown in orange. The work of Boehlke and colleagues (2010) shows that the LKB1
tumor suppressor kinase is located in the primary cilium, whereas its substrate, the AMP-dependent
protein kinase (AMPK), is found in the basal body. Upon cilium bending by fluid flow, LKB1 is activated
and transported into the basal body, where AMPK is phosphorylated (on the threonine-172 of the a cata-
lytic subunit) and activated. Stimulation of the LKB1-AMPK signaling leads to the downregulation of the
mTORC1 pathway and subsequent reduction of cell size via the inhibition of protein synthesis. The primary
cilium may act as a glucose-sensing antenna (see Boehlke et al., 2010) or may be involved in polarized
migration toward a chemotactic source, producing factors such as PDGF. In these two latter situations
involving the primary cilium, the LKB1-mTORC1 pathway may also be involved in transducing intracellular
signals.
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Previewsinhibits mTORC1 activity, alleviated renal
cystic symptoms in animal models of
PKD (Shillingford et al., 2006). Recent
findings published by Boehlke and
colleagues in Nature Cell Biology have
now provided insight into this important
question (Boehlke et al., 2010) (Figure 1).
The mTORC1 complex comprises
the mTOR serine/threonine kinase, the
regulatory adaptor protein Raptor, and
another set of binding partners (Sengupta
et al., 2010). It is well documented that
mTORC1 controls cell size through
the phosphorylation of key elements ofthe translational machinery, such as the
S6 kinases (S6Ks) and eIF4E-binding
proteins (Sengupta et al., 2010). To
examine whether cilium bending may
modulate renal cell size, the authors first
focused their attention on Kif3a, a kinesin
that ferries components of the cilium
along the microtubule axoneme (Boehlke
et al., 2010). Consistent with the hypoth-
esis, inactivation of Kif3a in postnatal
mouse kidneys led to the enlargement of
collecting duct cells. To obtain a tractable
model system that allowed for the anal-
ysis of underlying processes, the authorsDevelopmental Cell 19, Dused Madin-Darby canine epithelial cells
(MDCK). Depletion of Kif3A by RNA inter-
ference (RNAi) prevented the formation of
primary cilia in MDCK cells but without
substantial impact on cell size compared
to the control. However, when cells were
incubated in a flow chamber and sub-
jected to a permanent fluid flow for
6 days to mimic the hydrodynamic
conditions faced by renal cells, MDCK
cells without cilium were significantly
larger than the wild-type MDCK cells.
Similar results were produced through
the inhibition of Ift88 expression, an
essential component of the IFT. Next,
the authors demonstrated the involve-
ment of mTORC1 activity in this pheno-
type through several approaches. First,
they showed that the phosphorylation of
mTOR and S6K was reduced in wild-
type, but not Kif3a knockdown MDCK
cells subjected to fluid flow. Second,
treatment with rapamycin or inactivation
of Raptor in Kif-3a-depleted MDCK cells
led to a cell size decrease in flow chamber
conditions. Finally, the expression in
MDCK cells of a constitutive activator of
mTOR—a Rheb gain-of-function allele—
induced an augmentation of cell volume
under flow conditions.
Taken together, the above findings
indicated that the downregulation of
mTORC1 is caused by cilium bending
but left untouched the question of the
mechanisms that translate mechanosen-
sory cues into a signal converging on
mTORC1. An intuitive hypothesis was
that the Ca2+ signal mediated by polycys-
tin 2 in response to cilium deflection
was relayed to mTORC1. However, the
authors tested and refuted this idea. In
pursuing their investigation, they came
upon a thought-provoking answer. The
LKB1 tumor suppressor kinase is an
essential regulator of cell polarity and
energy metabolism, two functions partly
coordinated through the activation of the
AMP-activated protein kinase (AMPK)
(Hezel and Bardeesy, 2008). AMPK
senses metabolic stress and maintains
energy balance by switching off anabolic
processes that consume ATP, including
protein synthesis (Viollet et al., 2010).
Because the LKB1-AMPK pathway
inhibits mTOR activity, Boehlke et al.
concentrated on this branch of the
signaling network, and their efforts paid
off. They found that LKB1 localized to
the cilium, whereas AMPK was restrictedecember 14, 2010 ª2010 Elsevier Inc. 793
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Previewsto the basal body (Figure 1). Furthermore,
AMPK showed increased phosphoryla-
tion of the threonine residue recognized
by LKB1 in the basal body when cells
were incubated in flow conditions. Finally,
LKB1-depleted MDCK cells were larger
under flow, and phosphorylation of S6K
was enhanced compared to wild-type
MDCK cells subjected to the same condi-
tions. Together, these results suggest that
bending of the cilium promotes relocaliza-
tion of LKB1 in the basal body at close
proximity of its substrate AMPK, whose
activation restrains mTORC1 signaling.
As typical for scientific discoveries,
fresh insights in turn raise new questions.
For example, how is LKB1 recruited to the
primary cilium, and what are the mecha-
nisms that couple cilium bending and
activation of the LKB1-AMPK pathway?
The LKB1 holoenzyme is a heterotrimer
comprising the pseudokinase STRAD
(STRADa and STRADb) and the scaf-
folding protein MO25 (MO-25a and MO-
25b) (Hezel and Bardeesy, 2008). It is
likely that these LKB1 partners associate
with LKB1 in the cilium and contribute to
LKB1 transport or function. Moreover,
LKB1 is the target of several posttransla-
tional modifications that modulate its
activity (Hezel and Bardeesy, 2008),
such as phosphorylation and acetylation,
and it would be important to examine
whether these changes correlate with
cilium deflection. The spatial organization
of the LKB1-AMPK-mTORC1 pathway in
cells also deserves further analysis.
Patients with Peutz-Jeghers syndrome,
an inherited condition due to an inactivat-
ing germline mutation in LKB1, have not
been reported to be affected with renal794 Developmental Cell 19, December 14, 20diseases (Hezel and Bardeesy, 2008).
Thus, it is likely that LKB1 mutations are
not haploinsufficient in kidney cell, and it
will be important to study the conse-
quences of silencing both LKB1 alleles in
mouse kidneys. Similar full LKB1 deple-
tion in the mouse exocrine pancreas
results in pancreatic cystic tumor forma-
tion (Hezel et al., 2008), thus suggesting
that the LKB1-mTORC1 pathway func-
tions in primary cilia of pancreatic-epithe-
lial cells. Because this type of cilia may not
function in flow sensing, it is tempting to
speculate that additional stimuli activate
the LKB1-mTORC1pathway in this organ-
elle. Following this type of reasoning, the
authors pointed out that the glucose
transporter 2 (GLUT2) is localized to the
cilium, raising the idea that it may act as
a glucose-sensing antennae, a function
that would be consistent with the role of
LKB1 and AMPK in the regulation of ener-
getic metabolism (Figure 1). Another hint
comes from the study of a rare disorder
called PMSE that is characterized by poly-
hydramnios, megalencephaly, and symp-
tomatic epilepsy (Puffenberger et al.,
2007). The underlying genetic cause of
this disease is a homozygous deletion
of STRADa, and histological analysis
revealed cytomegalic neurons in PMSE
cortex (Orlova et al., 2010). Because the
inactivation of STRADa in neuron cultures
leads to mTORC1 activation (Orlova et al.,
2010), it is plausible that the LKB1-
mTORC1 pathway exhibits unanticipated
functions in the cortical neuron cilium.
Lastly, metformin is an antidiabetic
biguanide that is both an indirect stimu-
lator of AMPK and an mTORC1 inhibitor
(Viollet et al., 2010; Kalender et al.,10 ª2010 Elsevier Inc.2010). The findings of Boehlke and
coworkers (2010) suggest that this com-
pound, or the novel generation of AMPK
activators, may find useful therapeutic
applications in the treatment of PKD and
other ciliopathies.REFERENCES
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